Google
SCNX — SCIENTURE HOLDINGS, INC. (Healthcare >> Pharmaceutical Retailers)
SCNX FAQ
What is SCNX's ROE?
SCIENTURE HOLDINGS, INC. reports a Return on Equity (ROE) of -0.06%.
What is SCNX's dividend yield?
SCIENTURE HOLDINGS, INC. offers a dividend yield of 0.00%.
What is SCNX's Deepscope Quality Score?
Deepscope rates SCNX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SCNX?
Deepscope's AI Timing Score for SCNX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SCNX belong to?
SCIENTURE HOLDINGS, INC. is classified under the Healthcare >> Pharmaceutical Retailers sector on the NASDAQ exchange.
|
USD 0.36
Price
-0.02
(-5.26%)
Day Change
|
|
|---|
SCNX, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.36 |
| PBV / Sector |
N/A / 0.05
|
| Earning Per Share | -0.98 |
| PE / Sector |
N/A / 0.13
|
| PEG or PE/Growth / Sector |
N/A / 0.00
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.14 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:02 |
| Symbol | SCNX |
| Name | SCIENTURE HOLDINGS, INC. |
| Sector | Healthcare >> Pharmaceutical Retailers |
| Market | NASDAQ |
| Listed Shares | 40.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.44 / 1.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 20 Austin Boulevard, Commack, NY, United States, 11725
Phone: 631) 670-6039
Website: https://scienture.com
Description: Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
ME vs SECTOR Healthcare >> Pharmaceutical Retailers
Click a bubble to view stock details · Bubble size represents market capitalization share
